|
Gene: TMCC2 |
Gene summary for TMCC2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMCC2 | Gene ID | 9911 |
Gene name | transmembrane and coiled-coil domain family 2 | |
Gene Alias | HUCEP11 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0006807 | UniProtAcc | O75069 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9911 | TMCC2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.90e-13 | 3.35e-01 | 0.0155 |
9911 | TMCC2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.75e-27 | 7.52e-01 | -0.1808 |
9911 | TMCC2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.50e-09 | 5.78e-01 | 0.0216 |
9911 | TMCC2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.09e-26 | 8.98e-01 | -0.0811 |
9911 | TMCC2 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.50e-11 | 5.21e-01 | -0.1088 |
9911 | TMCC2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.48e-28 | 6.39e-01 | -0.1954 |
9911 | TMCC2 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.06e-05 | 6.24e-01 | -0.2602 |
9911 | TMCC2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.91e-03 | 4.18e-01 | -0.2196 |
9911 | TMCC2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.02e-20 | 6.73e-01 | -0.1207 |
9911 | TMCC2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.02e-14 | 5.14e-01 | -0.1526 |
9911 | TMCC2 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.73e-16 | 3.78e-01 | -0.1464 |
9911 | TMCC2 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.47e-08 | 2.64e-01 | -0.1001 |
9911 | TMCC2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.65e-11 | 3.20e-01 | -0.059 |
9911 | TMCC2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.93e-08 | 5.78e-01 | -0.1706 |
9911 | TMCC2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.30e-08 | 4.71e-01 | -0.2061 |
9911 | TMCC2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.19e-07 | 6.23e-01 | -0.1462 |
9911 | TMCC2 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.71e-04 | 2.97e-01 | -0.0842 |
9911 | TMCC2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.13e-09 | 8.21e-01 | -0.00410000000000005 |
9911 | TMCC2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.76e-10 | 5.50e-01 | -0.0179 |
9911 | TMCC2 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.47e-22 | 6.00e-01 | 0.096 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMCC2 | SNV | Missense_Mutation | c.1416G>C | p.Lys472Asn | p.K472N | O75069 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TMCC2 | SNV | Missense_Mutation | rs761764527 | c.302C>T | p.Thr101Met | p.T101M | O75069 | protein_coding | tolerated_low_confidence(0.21) | benign(0.039) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TMCC2 | insertion | Frame_Shift_Ins | novel | c.249_250insTT | p.Leu84PhefsTer2 | p.L84Ffs*2 | O75069 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TMCC2 | SNV | Missense_Mutation | novel | c.307C>G | p.Gln103Glu | p.Q103E | O75069 | protein_coding | tolerated_low_confidence(0.15) | benign(0.023) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TMCC2 | SNV | Missense_Mutation | rs752001776 | c.829G>A | p.Asp277Asn | p.D277N | O75069 | protein_coding | deleterious(0.02) | benign(0.118) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
TMCC2 | SNV | Missense_Mutation | c.1009N>A | p.Glu337Lys | p.E337K | O75069 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
TMCC2 | deletion | Frame_Shift_Del | novel | c.98_108delTCCGGCCTGGG | p.Leu33ArgfsTer6 | p.L33Rfs*6 | O75069 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
TMCC2 | SNV | Missense_Mutation | c.1955N>T | p.Ala652Val | p.A652V | O75069 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
TMCC2 | SNV | Missense_Mutation | c.1201N>A | p.Gly401Ser | p.G401S | O75069 | protein_coding | deleterious(0.03) | possibly_damaging(0.817) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TMCC2 | SNV | Missense_Mutation | rs745395559 | c.784G>A | p.Ala262Thr | p.A262T | O75069 | protein_coding | tolerated(0.21) | benign(0.014) | TCGA-A6-A56B-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |